Navigation Links
BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
Date:10/25/2007

WOBURN, Mass., Oct. 25 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Jan van Heek, age 58, as Chairman of the Board of Directors.

Mr. van Heek is employed as a Senior Advisor to the CEO and the senior management team of Genzyme Corporation; he joined Genzyme in 1991 and has been responsible for building the Company's worldwide therapeutics, surgical and genetic testing businesses. He established Genzyme's European offices in the early 1990's before moving to the U.S. to head the Company's therapeutics division. Mr. van Heek has played a key role in building Genzyme's broad portfolio of businesses and manufacturing infrastructure worldwide. Prior to Genzyme, Mr. van Heek held various management positions at Baxter Healthcare Corporation in Europe and the U.S. At Baxter, his last position was as vice president/general manager of the global Fenwal Division of Baxter Healthcare Corporation based in Deerfield, Illinois. Mr. van Heek is a board member of Viacell Corporation, Zelos Corporation and PanGenetics BV. He received an M.B.A. from St. Gallen University, Switzerland and an executive degree from Stanford Business School, California.

Philip Astley-Sparke, President & CEO of BioVex Inc, said:

"Jan's appointment brings to the Board nearly two decades of experience in managing the commercial and manufacturing operations of one the world's preeminent biotechnology companies."

Jan van Heek, Chairman of BioVex Inc, said:

"I am excited to be joining BioVex at a transformational time in its development as it scales up its manufacturing operations to produce launch grade material. I look forward to working with the management team, the Board and the Company's investors in implementing the Company's substantial growth plans over the next year and beyond."

About BioVex

BioVex is a privately held bi
'/>"/>

SOURCE BioVex Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ ... report to their offering. The ... a CAGR of 22.7% from 2014 to 2019. Factors ... treatment, growing adoption of companion diagnostics by the pharmaceutical ...
(Date:9/18/2014)... -- U.S. biotech company Kultevat has strengthened its ... developed by the Donald Danforth Plant Science Center ... applications in production of natural rubber in Taraxicum ... under the direction of Roger Beachy , Ph.D., ... the Danforth Plant Science Center, and is used to ...
(Date:9/18/2014)... Sept. 18, 2014  Neogen Corporation (Nasdaq: ... a strategic agreement with Merck Animal Health to market ... The Igenity Dairy Heifer Program consists of genomic ... the genetic potential of replacement dairy heifers. The genomic ... born, and is an excellent tool in the decision-making ...
(Date:9/18/2014)... Pennsylvanie, 18 septembre 2014 Mapi, ... en 1974, a été depuis 40 ans ... évaluations cliniques traditionnelles par des évaluations recentrées ... sur les impacts économiques des traitements. ... A cours d,une récente conférence ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... 7 Amsterdam Molecular,Therapeutics (Euronext: AMT), a leader ... the treatment of the first patient in a ... targets,lipoprotein lipase deficiency (LPLD), a seriously debilitating and,potentially ... randomized controlled trial has been designed to gather ...
... Kendle (Nasdaq: KNDL ), a leading, global ... or $0.06 per share for the first quarter 2009 compared ... share for the first quarter 2008. On a pro forma ... $0.47 per diluted share compared with $0.38 per diluted share ...
... Amgen (Nasdaq: AMGN ), today announced ... Stockholders, held at The St. Regis Hotel, San Francisco, ... represented at the meeting.The director nominees: David Baltimore, Frank ... Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer, ...
Cached Biology Technology:AMT Starts Preregistration Trial for Glybera(TM) 2AMT Starts Preregistration Trial for Glybera(TM) 3Kendle Announces First Quarter 2009 Results 2Kendle Announces First Quarter 2009 Results 3Kendle Announces First Quarter 2009 Results 4Kendle Announces First Quarter 2009 Results 5Kendle Announces First Quarter 2009 Results 6Kendle Announces First Quarter 2009 Results 7Kendle Announces First Quarter 2009 Results 8Amgen Announces Voting Results Of Annual Meeting Of Stockholders 2
(Date:9/19/2014)... A new study shows that legume plants regulate ... cytokininssignaling molecules that are transmitted through the plant ... the number of bacteria-holding nodules in the roots. ... the National Institute for Basic Biology, the Graduate ... Center for Sustainable Resource Science in Japan. ...
(Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive brainstem ... by researchers at Harvard School of Medicine and the ... this is only the second "sleep node" identified in ... necessary and sufficient to produce deep sleep. , Published ... study demonstrates that fully half of all of the ...
(Date:9/18/2014)... robotic system that can operate inside the bore of ... of a biomedical research partnership program at Brigham and ... if the robot, in conjunction with real-time MRI images, ... costly, and less discomforting for the patient. The novel ... therapies with greater precision. , Developed by a team ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... harnessing of 'T-rays' - electromagnetic terahertz waves - which ... varied as biological cell abnormalities and explosives has been announced. ... in Spain have said they have found a way to ... Their findings are set out in a letter published in ...
... heart is removed, the dynamic interplay between a mass ... the protective cell layer that covers the wound spurs ... Medical Center scientists have found. , The scientists further ... the cell mass and the protective covering, encouraging the ...
... Institute of Virology and Immunology (GIVI) have identified a previously ... HIV, a finding that may lead to new approaches for ... Oct. 2, 2006, in Proceedings of the National Academy of ... laboratory of GIVI Director Warner C. Greene, MD, PhD, explains ...
Cached Biology News:T-ray breakthrough could make detecting disease far easier 2Key to zebrafish heart regeneration uncovered 2Key to zebrafish heart regeneration uncovered 3Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
...
Mouse monoclonal [CAT-2] to Chloramphenicol Acetyltransferase...
Recommended fro Western blotting application...
Biology Products: